JP2019514945A5 - - Google Patents

Download PDF

Info

Publication number
JP2019514945A5
JP2019514945A5 JP2018557398A JP2018557398A JP2019514945A5 JP 2019514945 A5 JP2019514945 A5 JP 2019514945A5 JP 2018557398 A JP2018557398 A JP 2018557398A JP 2018557398 A JP2018557398 A JP 2018557398A JP 2019514945 A5 JP2019514945 A5 JP 2019514945A5
Authority
JP
Japan
Prior art keywords
formula
compound
general formula
acute
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018557398A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019514945A (ja
JP6932140B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/060356 external-priority patent/WO2017191102A1/en
Publication of JP2019514945A publication Critical patent/JP2019514945A/ja
Publication of JP2019514945A5 publication Critical patent/JP2019514945A5/ja
Application granted granted Critical
Publication of JP6932140B2 publication Critical patent/JP6932140B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018557398A 2016-05-03 2017-05-02 アミド置換ピリジニルトリアゾール誘導体およびその用途 Expired - Fee Related JP6932140B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16168165.5 2016-05-03
EP16168165 2016-05-03
PCT/EP2017/060356 WO2017191102A1 (en) 2016-05-03 2017-05-02 Amide-substituted pyridinyltriazole derivatives and uses thereof

Publications (3)

Publication Number Publication Date
JP2019514945A JP2019514945A (ja) 2019-06-06
JP2019514945A5 true JP2019514945A5 (enExample) 2020-06-11
JP6932140B2 JP6932140B2 (ja) 2021-09-08

Family

ID=55910850

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018557398A Expired - Fee Related JP6932140B2 (ja) 2016-05-03 2017-05-02 アミド置換ピリジニルトリアゾール誘導体およびその用途

Country Status (42)

Country Link
US (4) US9988367B2 (enExample)
EP (1) EP3452463B1 (enExample)
JP (1) JP6932140B2 (enExample)
KR (1) KR20190003655A (enExample)
CN (2) CN109415347B (enExample)
AR (1) AR108262A1 (enExample)
AU (1) AU2017259870B2 (enExample)
BR (1) BR112018072542A2 (enExample)
CA (1) CA3022749A1 (enExample)
CL (1) CL2018003105A1 (enExample)
CO (1) CO2018011933A2 (enExample)
CR (1) CR20180522A (enExample)
CU (1) CU24567B1 (enExample)
CY (1) CY1124084T1 (enExample)
DK (1) DK3452463T3 (enExample)
DO (1) DOP2018000240A (enExample)
EA (1) EA035596B1 (enExample)
EC (1) ECSP18081881A (enExample)
ES (1) ES2866109T3 (enExample)
GE (2) GEP20207158B (enExample)
HR (1) HRP20210648T1 (enExample)
HU (1) HUE053908T2 (enExample)
IL (1) IL262557B (enExample)
JO (1) JOP20170105B1 (enExample)
LT (1) LT3452463T (enExample)
MA (1) MA44851B1 (enExample)
MX (1) MX381787B (enExample)
NI (1) NI201800115A (enExample)
PE (1) PE20190116A1 (enExample)
PH (1) PH12018502268A1 (enExample)
PL (1) PL3452463T3 (enExample)
PT (1) PT3452463T (enExample)
RS (1) RS61771B1 (enExample)
SG (1) SG11201809752VA (enExample)
SI (1) SI3452463T1 (enExample)
SV (1) SV2018005771A (enExample)
TN (1) TN2018000368A1 (enExample)
TW (1) TWI772295B (enExample)
UA (1) UA123791C2 (enExample)
UY (1) UY37220A (enExample)
WO (1) WO2017191102A1 (enExample)
ZA (1) ZA201808131B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3458443B1 (en) 2016-05-03 2020-08-19 Bayer Pharma Aktiengesellschaft Aromatic sulfonamide derivatives
US9988367B2 (en) * 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
CN109071464A (zh) * 2016-05-03 2018-12-21 拜耳制药股份公司 氧代烷基取代的苯基三唑衍生物及其用途
KR20190003536A (ko) * 2016-05-03 2019-01-09 바이엘 파마 악티엔게젤샤프트 5-히드록시알킬-치환된 1-페닐-1,2,4-트리아졸 유도체의 제조 방법
US10893352B2 (en) * 2016-08-24 2021-01-12 Matthew Hawkes Programmable interactive stereo headphones with tap functionality and network connectivity
WO2018163204A1 (en) * 2017-03-08 2018-09-13 Yogee's Bioinnovations Private Limited Cathepsin-d and angiogenesis inhibitors and compositions thereof for treating breast cancer
EP3665705B1 (en) 2017-08-08 2024-12-18 Fresenius Medical Care Holdings, Inc. Systems and methods for treating and estimating progression of chronic kidney disease
WO2019081306A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
EP3700896A1 (en) 2017-10-24 2020-09-02 Bayer Pharma Aktiengesellschaft Amine substituted triazole derivatives and uses thereof
CA3084308A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft Substituted triazole derivatives and uses thereof
EP3700897A1 (en) 2017-10-24 2020-09-02 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
KR20200069361A (ko) * 2017-10-24 2020-06-16 바이엘 악티엔게젤샤프트 치환된 트리아졸 유도체의 전구약물 및 그의 용도
WO2019081303A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
WO2019081291A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft PRODRUGS OF SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素V1a受體拮抗劑之三環化合物
US11020351B2 (en) * 2018-03-26 2021-06-01 Hetero Labs Limited Stable bilayer tablet compositions
WO2019199273A1 (en) * 2018-04-10 2019-10-17 Hewlett-Packard Development Company, L.P. Preheat dyed build materials with preheating sources
KR20260018202A (ko) * 2019-12-24 2026-02-06 도쿄엘렉트론가부시키가이샤 성막 방법 및 성막 시스템
WO2021252951A1 (en) 2020-06-12 2021-12-16 Vanderbilt University Methods of treatment for gastrointestinal motility disorders
WO2021259852A1 (en) 2020-06-25 2021-12-30 Bayer Aktiengesellschaft Process for preparing 5-(alkoxycarbonyl)-and 5-(carboxamide)-1-aryl-1,2,4-triazole derivatives
WO2022112213A1 (en) 2020-11-30 2022-06-02 Bayer Aktiengesellschaft Crystalline forms of 3-[[3-(4-chlorophenyl)-5-oxo-4-((2s)-3,3,3-trifluoro- 2-hydroxypropyl)-4,5-dihydro-1h-1,2,4-triazol-1-yl]methyl]-1-[3- (trifluoromethyl)pyridin-2-yl]-1h-1,2,4-triazole-5-carboxamide
WO2024118667A1 (en) * 2022-11-29 2024-06-06 The United States Government As Represented By The Department Of Veterans Affairs Eif4a1 inhibitors with antitumor activity
WO2026035773A1 (en) * 2024-08-06 2026-02-12 Retex Pharmaceuticals, Inc. Vasopressin receptor 2 modulators and methods of use thereof

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3042466A1 (de) 1980-11-11 1982-06-16 A. Nattermann & Cie GmbH, 5000 Köln N-substituierte (omega) -(2-oxo-4-imidazolin-l-yl)-alkansaeure-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
US5468448A (en) 1989-12-28 1995-11-21 Ciba-Geigy Corporation Peroxide disinfection method and devices therefor
DE4107857A1 (de) 1991-03-12 1992-09-17 Thomae Gmbh Dr K Cyclische harnstoffderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
EP0586513A1 (en) 1991-05-10 1994-03-16 Merck & Co. Inc. Acidic aralkyl triazole derivatives active as angiotensin ii antagonists
WO1993017681A1 (en) 1992-03-02 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
SK94393A3 (en) 1992-09-11 1994-08-10 Thomae Gmbh Dr K Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US6844005B2 (en) 2002-02-25 2005-01-18 Trutek Corp Electrostatically charged nasal application product with increased strength
FR2708608B1 (fr) 1993-07-30 1995-10-27 Sanofi Sa Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant.
US5897858A (en) 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
US20010020100A1 (en) 1994-06-14 2001-09-06 G.D. Searle & Co. N-substituted-1, 2, 4-triazolone compounds for treatment of cardiovascular disorders
HUP0100178A3 (en) 1997-12-17 2002-12-28 Merck & Co Inc Tetrahydro-naphtiridinyl-imidazolydinyl-carboxylic acid derivatives and pharmaceutical compositions thereof
DE19816882A1 (de) 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Triazolone mit neuroprotektiver Wirkung
BR9912392A (pt) 1998-07-24 2001-05-08 Bayer Ag Benzoilcicloexanodionas substituìdas
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19914140A1 (de) 1999-03-27 2000-09-28 Bayer Ag Substituierte Benzoylpyrazole
KR20020005653A (ko) 1999-04-01 2002-01-17 실버스타인 아써 에이. 소르비톨 디하이드로게나제 저해제로서의 아미노피리미딘
DE19920791A1 (de) 1999-05-06 2000-11-09 Bayer Ag Substituierte Benzoylisoxazole
DE19921424A1 (de) 1999-05-08 2000-11-09 Bayer Ag Substituierte Benzoylketone
DE19929348A1 (de) 1999-06-26 2000-12-28 Bayer Ag Verfahren zur Herstellung von 2-Heterocyclylmethyl-benzoesäurederivaten
US6531142B1 (en) 1999-08-18 2003-03-11 The Procter & Gamble Company Stable, electrostatically sprayable topical compositions
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR027575A1 (es) 2000-03-06 2003-04-02 Bayer Ag Benzoilciclohexenonas substituidas
US7080644B2 (en) 2000-06-28 2006-07-25 Microdose Technologies, Inc. Packaging and delivery of pharmaceuticals and drugs
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
WO2002066447A1 (en) 2001-02-21 2002-08-29 Ono Pharmaceutical Co., Ltd. 4h-1,2,4-triazole-3(2h)-thione deratives as sphingomyelinase inhibitors
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
US20040071757A1 (en) 2001-11-20 2004-04-15 David Rolf Inhalation antiviral patch
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
CA2518852A1 (en) 2003-03-14 2004-09-30 Merck & Co., Inc. Monocyclic anilide spirohydantoin cgrp receptor antagonists
EP1689252A2 (en) 2003-06-27 2006-08-16 Berglin Corporation of Washington Machine for precision low stress coring and slicing of apples and other soft-cored or pitted fruits
BRPI0417267A (pt) * 2003-12-22 2007-04-17 Pfizer derivados de triazol como antagonistas de vasopressina
CN1933832A (zh) 2004-03-08 2007-03-21 惠氏公司 离子通道调节剂
EP1723117A4 (en) 2004-03-08 2009-12-02 Wyeth Corp ION CHANNEL MODULATORS
CA2563963A1 (en) 2004-04-28 2005-11-10 Pfizer Inc. 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor
WO2006066133A2 (en) 2004-12-16 2006-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2006117657A1 (en) 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Triazolone derivatives as anti-inflammatory agents
DE102006024024A1 (de) 2006-05-23 2007-11-29 Bayer Healthcare Aktiengesellschaft Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung
DE102008060967A1 (de) 2008-12-06 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylsulfonyltriazolone und ihre Verwendung
DE102009013642A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylalaninderivate und deren Verwendung
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
DE102009028929A1 (de) 2009-08-27 2011-07-07 Bayer Schering Pharma Aktiengesellschaft, 13353 Heterocyclisch-substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
AU2011219746B2 (en) 2010-02-27 2015-04-23 Bayer Intellectual Property Gmbh Bisaryl-bonded aryltriazolones and use thereof
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
PH12013500055A1 (en) 2010-07-09 2017-08-23 Bayer Ip Gmbh Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases
DE102010040187A1 (de) 2010-09-02 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Substituierte N-Phenethyl-triazolonacetamide und ihre Verwendung
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
EP2623499B1 (en) * 2010-10-01 2015-04-22 Taisho Pharmaceutical Co., Ltd 1,2,4-triazolone derivative
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
WO2012112363A1 (en) 2011-02-14 2012-08-23 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
EP2828257B1 (en) 2012-03-22 2017-07-26 Biota Europe Ltd Antibacterial compounds
EA032137B1 (ru) 2014-11-03 2019-04-30 Байер Фарма Акциенгезельшафт Производные гидроксиалкил-замещенного фенилтриазола и их применение
KR20190003536A (ko) * 2016-05-03 2019-01-09 바이엘 파마 악티엔게젤샤프트 5-히드록시알킬-치환된 1-페닐-1,2,4-트리아졸 유도체의 제조 방법
US9988367B2 (en) * 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
CN109071464A (zh) * 2016-05-03 2018-12-21 拜耳制药股份公司 氧代烷基取代的苯基三唑衍生物及其用途

Similar Documents

Publication Publication Date Title
JP2019514945A5 (enExample)
HRP20210648T1 (hr) Amid-supstituirani derivati piridiniltriazola i njihova uporaba
TW544453B (en) Novel guanidine mimics as factor Xa inhibitors
DE3750687T2 (de) Angiotensin II-Rezeptorblockierende Imidazole.
JP4680903B2 (ja) ピリダジニル−ピペラジンおよびそれらのヒスタミンh3受容体リガンドとしての使用
JP4463317B2 (ja) 置換イミダゾールおよび殺虫剤としてのその使用
SA517381429B1 (ar) مشتقات فينيل تريازول مستبدلة مع هيدروكسي ألكيل واستخداماتها
AU2014272776C1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
AU2010200135A1 (en) Novel aryl-and heteroarylpiperazines
JP2010515715A5 (enExample)
JP2006504658A5 (enExample)
CA2262252C (en) Method of treating heart failure
JP2000514088A (ja) グルカゴンアンタゴニストとしてのトリアリール置換イミダゾール
JP2010507602A5 (enExample)
JP2002080453A (ja) 選択的シクロオキシゲナーゼ−2阻害物質となる置換ピリジン
CN106304835A (zh) sGC刺激剂
JP2002520274A (ja) バルサルタンとカルシウムチャンネルブロッカーの抗高血圧組合わせ
TWI772309B (zh) 化合物及其於降低尿酸位準之用途(二)
JP2003513961A (ja) シクロオキシゲナーゼ−2の阻害剤である5−アリール−1h−1,2,4−トリアゾール化合物とそれを含む医薬品組成物
CZ280018B6 (cs) 4-alkylimidazolové deriváty
JP2014532726A5 (enExample)
WO2017013010A1 (de) Stimulatoren und/oder aktivatoren der löslichen guanylatzyklase (sgc) in kombination mit einem inhibitor der neutralen endopeptidase (nep inhibitor) und/oder einem angiotensin aii-antagonisten und ihre verwendung
JP2012509858A (ja) 肥大性心筋症治療用のホスホジエステラーゼタイプIII(PDEIII)インヒビターまたはCa2+感作剤
Carmignani et al. Novel hypotensive agents from Verbesina c aracasana. 8. Synthesis and pharmacology of (3, 4-Dimethoxycinnamoyl)-N-agmatine and Synthetic Analogues1
JP2012503005A5 (enExample)